Linganisha mbinu

	Acne-QoL (Kipimo cha Ubora wa Maisha kwa Chunusi)	cDLQI	Skindex-29 (Kipimo cha Ubora wa Maisha wa Magonjwa ya Ngozi)
Nyanja	Dermatolojia	Dermatolojia	Dermatolojia
Familia	Process / pipeline	Process / pipeline	Process / pipeline
Mwaka wa asili	2004	1995	1997
Mwanzilishi	Halvorsen JA et al.	Lewis-Jones MS, Finlay AY	Chren MM, Lasek RJ
Aina	Self-report	Self-report (parent or child proxy)	Self-report
Chanzo asilia	Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363-370.	Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
Majina mbadala	Acne-Q, Acne-Specific QoL	cDLQI, Pediatric DLQI	Skindex, Skindex-QoL
Zinazohusiana	4	3	1
Muhtasari	Acne-QoL is a disease-specific, patient-administered quality-of-life measure assessing the psychological and social burden of acne vulgaris. Acne is the most common skin disease in adolescents and young adults and causes substantial psychological distress, depression, anxiety, and social impairment disproportionate to its severity. Multiple versions of Acne-QoL exist (19–24 items); all capture emotional, social, and functional impacts. Acne-QoL is essential in clinical trials and observational studies to ensure treatment efficacy encompasses quality-of-life outcomes.	The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.